Trials / Unknown
UnknownNCT03971747
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Shanghai AbelZeta Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
Detailed description
This study plans to enroll 9 patients to assess the safety of C-TCR055. Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFP Specific T Cell Receptor T Cells | Autologous T cells transduced with lentivirus encoding AFP specific TCR gene |
Timeline
- Start date
- 2019-08-06
- Primary completion
- 2020-06-01
- Completion
- 2021-04-01
- First posted
- 2019-06-03
- Last updated
- 2020-04-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03971747. Inclusion in this directory is not an endorsement.